接受静脉-静脉体外膜肺氧合治疗新型冠状病毒肺炎急性呼吸窘迫综合征患者的死亡危险因素
Risk Factors of Mortality for Patients Receiving Venovenous Extracorporeal Membrane Oxygenation for COVID-19 Acute Respiratory Distress Syndrome.
作者信息
Bergman Zachary R, Wothe Jillian K, Alwan Fatima S, Lofrano Arianna E, Tointon Kelly M, Doucette Melissa, Bohman John K, Saavedra-Romero Ramiro, Prekker Matthew E, Lusczek Elizabeth R, Beilman Greg, Brunsvold Melissa E
机构信息
Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
出版信息
Surg Infect (Larchmt). 2021 Dec;22(10):1086-1092. doi: 10.1089/sur.2021.114. Epub 2021 Sep 6.
Venovenous extracorporeal membrane oxygenation (VV-ECMO) for select adults with severe acute respiratory distress syndrome (ARDS) cause by coronavirus disease 2019 (COVID-19) infection is a guideline-supported therapy with associated hospital survival of 62%-74%, similar to expected survival with VV-ECMO for other indications. However, ECMO is a resource-heavy intervention, and these patients often require long ECMO runs and prolonged intensive care unit (ICU) care. Identifying factors associated with mortality in VV-ECMO patients with COVID-19 infection can inform the evaluation of ECMO candidates as well as prognostication for those patients on prolonged VV-ECMO. This was a retrospective cohort study that included all patients who received either VV- or venoarteriovenous (VAV)-ECMO at one of four ECMO Centers of Excellence in the state of Minnesota between March 1, 2020 and November 1, 2020. The primary outcome was 60-day survival. Secondary outcomes were hospital complications, infectious complications, and complications from ECMO. There were 46 patients who met criteria during this study period and 30 survived to 60-day follow-up (65.2%). Prior to cannulation, older patient age (55.5 in non-survivors vs. 49.1 years in survivors; p = 0.03), lower P/F ratio (62.1 vs. 76.2; p = 0.04), and higher sequential organ failure assessment (SOFA) score (8.1 vs. 6.6; p = 0.02) were identified as risk factors for mortality. After ECMO cannulation, increased mortality was associated with increased number of antibiotic days (25.9 vs. 14.5; p = 0.04), increased number of transfusions (23.9 vs. 9.9; p = 0.03), elevated white blood cell (WBC) count at post-ECMO days one through three, elevated D-dimer at post-ECMO day 21-27, and decreased platelet count from post-ECMO days 14 and onward using univariable analysis. Multiple markers of infection including leukocytosis, thrombocytopenia, and increased antibiotic days are associated with increased mortality in patients placed on VV-ECMO for COVID-19 infection and subsequent ARDS. Knowledge of these factors may assist with determining appropriate candidates for this limited resource as well as direct goals of care in prolonged ECMO courses.
对于由2019冠状病毒病(COVID-19)感染引起的严重急性呼吸窘迫综合征(ARDS)的特定成人患者,静脉-静脉体外膜肺氧合(VV-ECMO)是一种有指南支持的治疗方法,其相关的医院生存率为62%-74%,与VV-ECMO用于其他适应症时的预期生存率相似。然而,ECMO是一种资源密集型干预措施,这些患者通常需要长时间使用ECMO以及延长在重症监护病房(ICU)的护理时间。确定COVID-19感染的VV-ECMO患者的死亡相关因素,可以为评估ECMO候选者以及对那些长时间使用VV-ECMO的患者进行预后判断提供依据。这是一项回顾性队列研究,纳入了2020年3月1日至2020年11月1日期间在明尼苏达州四个卓越ECMO中心之一接受VV-或静脉-动脉-静脉(VAV)-ECMO治疗的所有患者。主要结局是60天生存率。次要结局是医院并发症、感染性并发症和ECMO相关并发症。在本研究期间有46名患者符合标准,30名患者存活至60天随访期(65.2%)。在插管前,年龄较大(非存活者为55.5岁,存活者为49.1岁;p = 0.03)、较低的P/F比值(62.1对76.2;p = 0.04)以及较高的序贯器官衰竭评估(SOFA)评分(8.1对6.6;p = 0.02)被确定为死亡的危险因素。在ECMO插管后,通过单变量分析发现,抗生素使用天数增加(25.9天对14.5天;p = 0.04)、输血次数增加(23.9次对9.9次;p = 0.03)、ECMO后第1至3天白细胞(WBC)计数升高、ECMO后第21至27天D-二聚体升高以及ECMO后第14天及以后血小板计数降低与死亡率增加相关。包括白细胞增多、血小板减少和抗生素使用天数增加在内的多种感染标志物与因COVID-19感染及随后的ARDS而接受VV-ECMO治疗的患者死亡率增加相关。了解这些因素可能有助于确定这种有限资源的合适候选者,并指导长时间ECMO治疗过程中的护理目标。